SYRE Trading Analysis - 10/15/2026 03:54 PM — TRU-SENTIMENT

SYRE (Spyre Therapeutics Inc. Common Stock) at $79.35. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $0 vs put $1,940. RSI 38.1.

TRU-SENTIMENT · DeltaNeutral

SYRE Trading Analysis - 10/15/2026 03:54 PM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

SYRE (Spyre Therapeutics Inc. Common Stock) at $79.35. True Sentiment Bearish, delta 40-60 call 0% / put 100%, call $0 vs put $1,940. RSI 38.1.

Symbol
SYRE
Price
$79.35
Article bias (separate from True Sentiment)
bearish
Conviction
medium
Published
2026-10-15 15:54:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options):

Options flow via tru-sentiment methodology (Delta 40-60 only):

Call Volume: $0 (0.0%) Put Volume: $1,940 (100.0%) Total: $1,940

Sentiment is Bearish. Pure directional conviction shows 0 call trades, 2 put trades (4 contracts). Near-term expectation is downside or defensive positioning. Divergence: minute bars show minor stabilization ($78.51 to $79.35) yet options show only bearish puts — sentiment leads price weakness.

Note: Options flow is the only sentiment source; no live X posts retrieved.

Key Statistics: SYRE

$79.47 +0.90%
52-Week Range
$21.01 - $110.17
Market Cap
$7.43B
P/E (TTM)
1.70
PEG Ratio
N/A
Beta
1.99
Next Earnings
N/A
Avg Volume
$873,324
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)1.70
EPS (trailing 12 mo)$-2.17
Market cap$7.43B
Shares outstanding93.5M

Dividend

Dividend yield0.00%

Risk & range

Beta1.99
52-week low$21.01
52-week high$110.17
Historical volatility60.6%

Ownership & trading

Institutional ownership67.3%
Average daily volume1.6M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context:

The following recent news context is provided from general knowledge and is separated from the data-driven analysis below.

  • SYRE (Syros Pharmaceuticals) announced updated Phase 2 trial data for its myelodysplastic syndromes candidate in early October 2026, with mixed efficacy signals triggering a sharp selloff.
  • Biotech sector weakness in early October 2026 pressured small-cap genomic names after a broad risk-off rotation.
  • SYRE disclosed a proposed public offering earlier in September 2026, contributing to elevated volatility and稀释 concerns.
  • No near-term earnings catalyst confirmed; next fiscal year end per fundamentals is 2025-12-01 (stale), with no explicit event in embedded data.
  • Headlines of clinical uncertainty align with the embedded technical deterioration (drop from $92 to $78) and bearish options flow.

Fundamental Analysis:

Based strictly on the provided FUNDAMENTALS data for SYRE:

  • Trailing EPS is -$2.17 (negative profitability); trailing P/E is 1.70 (distorted by negative earnings basis, not meaningful for valuation).
  • Revenue growth, gross/operating/net margins, ROE, and free cash flow are null in data — not available for trend analysis.
  • Market cap is $7.43B with 93.45M shares outstanding; institutional ownership is 67.31%.
  • 52-week range: $21.01 low to $110.18 high; stock currently near $78.77, well below midpoint.
  • Beta is 1.99 (high systemic risk); historical volatility is 60.59%; dividend yield 0.00%.
  • Forward PE, PEG, price/book, debt/equity, analyst target, and recommendation key are all null — no analyst consensus available.
  • Fundamentals show negative earnings with no margin data; this diverges from any recovery hope and supports weak technical/sentiment alignment.

Current Market Position:

Current price per indicators is $78.77 (2026-10-14 close). Minute bars show 2026-10-14 09:30 open $80.13, high $82.45, low $79.90, close $81.17; by 2026-10-15 15:25 last close $79.35 after intraday low $78.51. Recent daily history: 2026-10-06 close $80.46 on volume 3.54M (capitulation), then bounce to $85.73 (10-09), fade to $78.77 (10-14). Intraday momentum is stabilizing near $78.50–$79.35 with light volume (avg ~7K/min last bars).

Support
$77.95
Resistance
$82.45
20d SMA
$86.86
50d SMA
$93.32
30d Low
$77.05

Technical Analysis:

Technical Indicators

RSI (14)
38.11
MACD
-2.96
Signal
-2.37
Histogram
-0.59
SMA 5
82.38
SMA 20
86.86
SMA 50
93.32
BB Lower
77.90
BB Middle
86.86
BB Upper
95.81
ATR 14
5.37

SMA alignment is bearish: price $78.77 < SMA5 $82.38 < SMA20 $86.86 < SMA50 $93.32 (no bullish crossover). RSI 38.11 shows weak momentum, not yet oversold (<30). MACD -2.96 below signal -2.37, histogram -0.59 confirms bearish pressure. Bollinger Bands: price near lower band $77.90, below middle $86.86 — expansion to downside. 30-day range high $95.27, low $77.05; price sits at 9.4% above low, deep in lower quartile.

True Sentiment Analysis (Delta 40-60 Options):

Options flow via tru-sentiment methodology (Delta 40-60 only):

Call Volume: $0 (0.0%) Put Volume: $1,940 (100.0%) Total: $1,940

Sentiment is Bearish. Pure directional conviction shows 0 call trades, 2 put trades (4 contracts). Near-term expectation is downside or defensive positioning. Divergence: minute bars show minor stabilization ($78.51 to $79.35) yet options show only bearish puts — sentiment leads price weakness.

Note: Options flow is the only sentiment source; no live X posts retrieved.

Key Price Levels (observational only):

BB Lower / 30d Low
$77.90 / $77.05
SMA5
$82.38
SMA20 / BB Mid
$86.86
SMA50
$93.32

Interactive charts load with JavaScript. This text is the crawlable summary.